Leah Kuntz

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

New analysis reveals Ingrezza achieves rapid symptomatic remission in tardive dyskinesia, enhancing patient quality of life and reducing disease burden.

New phase 2a study reveals promising results for BPL-003, with a 2-dose regimen improving outcomes for patients with treatment-resistant depression.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

Adial Pharmaceuticals has received feedback from FDA on the AD04 phase 3 adaptive clinical trial design and broader clinical development strategy.

Oregon's "Create Resilience" Youth Art Contest celebrates creativity in mental health, showcasing powerful youth submissions that inspire hope and connection.

Christine Yu Moutier, MD, discusses suicide prevention strategies, highlighting risk factors and the importance of culturally competent care for vulnerable populations.

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

Tonmya, the first new FDA-approved fibromyalgia treatment in 15 years, shows promise in reducing pain and improving patient outcomes according to newly released data.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Neuphoria Therapeutics announces successful enrollment in a pivotal trial for BNC-210, a promising treatment for social anxiety disorder.

A new guideline from the APA enhance the prevention and treatment of delirium, aiming to improve patient care and outcomes in clinical settings.

Submit to our September theme: Diagnosis Dilemmas!

Check out the pipeline updates from August!

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

PharmaTher's KETARx gains FDA approval, paving the way for innovative ketamine treatments in pain management and mental health disorders.

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

Check out the pipeline updates from July!

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.